Nabla — Funding & Company Data

Nabla's funding trajectory demonstrates a clear and accelerating confidence from the market. The initial Series A funding of $26 million, which included prominent angel investors, provided a solid base for product development and early market traction. The subsequent $24 million Series B in early 2024, led by Cathay Innovation, signaled a readiness to scale, particularly with a focus on the US healthcare market.

The most significant indicator of Nabla's potential is the recent $70 million Series C round. This large influx of capital, from a mix of new and existing investors including HV Capital and Highland Europe, at the Series C stage suggests that Nabla has successfully demonstrated product-market fit and is now in a rapid growth phase. The consistent participation of existing investors in later rounds is a strong vote of confidence in the company's leadership and long-term vision.

With $120 million in total funding, Nabla is well-capitalized to compete with other players in the ambient AI scribe market. This financial stability allows for aggressive investment in research and development to enhance their AI capabilities, expand their integration with various electronic health record (EHR) systems, and scale their sales and marketing efforts. The company's ability to attract high-quality investors also provides a strategic advantage, offering valuable networks and expertise in the healthcare technology sector. For potential customers, this strong financial backing translates to a lower risk of the company failing, ensuring the longevity and continued support of the product.